Nortran Pharmaceutical -NRT.V Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SOROS who wrote (650)	5/11/1998 12:45:00 PM
From: Edward W. Richmond	Read Replies (1) of 1185

Soros, I agree with your optimism about Nortran over the long term. My experience has shown that junior biotech stocks suffer from fickle investors (speculators) who will jump in and out of a stock quickly. This leaves Nortran, in the near term, vulnerable to great volatility that has nothing to do with real value. Also, shorter term investors, at least in my companies, tend to become bored after a stock reaches a plateau during the ongoing trials and further product development. This plateau, in my opinion, could be in the $3.50 to $4.50 range in Nortran's case. If there is a disappointment in the process, of course the stock will take a major hit. Nortran is protected to some degree by its multiple product line and the fact that a firm of the stature of Hoffmann-LaRoche has done its due diligence and decided to form the alliance. If the stock gets beaten down enough, I will add to my position. I'm looking to attending the AGM on Thursday. Perhaps I'll meet Wisee there. Regards, Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next